GRAIL Inc. (Nasdaq: GRAL) is scheduled to bring its Galleri multi-cancer blood test before a U.S. Food and Drug Administration advisory panel on September 23, 2026, following the release of agency briefing materials that identified no outstanding panel questions in several core review areas.
The FDA’s Molecular and Clinical Genetics Panel will discuss and vote on GRAIL’s premarket approval application. FDA staff said they had no outstanding questions for the panel regarding Galleri’s analytical performance, the concordance between the test versions used in clinical studies and submitted for approval, key elements of the study designs or the primary safety analyses.
The absence of outstanding questions in those areas is not an approval recommendation. The panel must still vote on whether Galleri is safe and effective and whether its probable benefits outweigh its probable risks. The FDA is not required to follow the panel’s recommendation when making its final decision.
A central question will be whether Galleri’s performance supports describing it as an “early detection” test. The FDA has asked advisers to consider whether the evidence supports that wording across different cancer types and stages or whether a broader “cancer detection” indication would be more appropriate.
Galleri is a prescription-only, next-generation sequencing test that analyzes cancer-related methylation patterns in cell-free DNA from a blood sample. When it detects a cancer signal, the test also predicts where that signal may have originated. It is intended for adults aged 50 and older and would supplement—not replace—established screening methods such as mammograms and colonoscopies.
FDA materials reported 12-month episode sensitivity of 35.0% in the PATHFINDER 2 study and 31.6% in the NHS-Galleri study. Specificity was 99.85% and 99.74%, respectively, while cancer-signal-origin accuracy exceeded 90% in both studies. However, performance varied among cancer types and stages.
The evidence also contains a material setback. The approximately 142,000-participant NHS-Galleri trial did not demonstrate a statistically significant reduction in combined Stage III and IV cancer diagnoses, its primary endpoint. GRAIL subsequently highlighted secondary findings, including reported reductions in Stage IV diagnoses among 12 prespecified aggressive cancers during later screening rounds.
When GRAIL completed its FDA application in January, CEO Josh Ofman called it “a critical step toward making Galleri available to more people.”
GRAIL reported second-quarter revenue of $44.7 million, including $42.6 million from Galleri, and a net loss of $110.2 million. Cash, cash equivalents and short-term marketable securities totaled $861.6 million as of June 30. The company expects continued operating losses over at least the next several years.
Upcoming Catalysts
- FDA advisory-panel discussion and votes on September 23
- The FDA’s final decision on Galleri’s premarket approval application
- Potential labeling limitations or post-approval study requirements
- Additional NHS-Galleri follow-up data
- Reimbursement and commercial-access developments if Galleri receives approval
Sources
- FDA Advisory Committee Meeting Announcement — September 23, 2026
- FDA Executive Summary for Galleri
- FDA Questions for the Galleri Advisory Panel
- Reuters: FDA Staff Flags No Major Concerns for Galleri — September 21, 2026
- GRAIL Reports Second-Quarter 2026 Financial Results
- GRAIL Form 10-Q for the Quarter Ended June 30, 2026
- GRAIL Reports Full NHS-Galleri Trial Results
Editorial Disclosure
This article is based entirely on publicly available information, including FDA materials, company announcements, SEC filings and publicly available news sources. Securities discussed or referenced include GRAIL Inc. (Nasdaq: GRAL). Biotech Stocks Daily has not received compensation from GRAIL, its management, investor relations representatives or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which do not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in any security mentioned at the time of publication.
Confirmed sources include the FDA’s Galleri advisory-committee announcement, executive summary and panel questions; GRAIL’s January 2026 premarket approval announcement, NHS-Galleri results and second-quarter financial results; the company’s SEC Form 10-Q for the quarter ended June 30, 2026; and Reuters reporting dated September 21, 2026.
Galleri has not been cleared or approved by the FDA. An advisory-panel recommendation is nonbinding and does not guarantee approval. A Galleri result does not constitute a cancer diagnosis, a negative result does not rule out cancer, and the test is not intended to replace guideline-recommended screening. The NHS-Galleri trial did not meet its primary endpoint, while selected favorable findings cited by GRAIL came from secondary analyses.
Financial information reflects GRAIL’s position as of June 30, 2026 and may have changed. The company continues to record substantial operating losses and expects losses to continue for at least several years. Its June 2026 equity financing increased available capital but also increased the number of outstanding shares.
Biotechnology and healthcare-technology securities are speculative investments carrying significant risk, including the potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making investment decisions. For more information, please see our full DISCLAIMER.
